ROX (Respiratory rate-OXygenation) index to predict early
response to high-flow nasal cannula therapy in infants with viral
bronchiolitis
Christophe Milesi1, Julien Baleine1,
Erika Nogue2, Lionel Moulis2 MD;
Robin Pouyau3; Arthur Gavotto1;
David Brosssier4; Guillaume
Mortamet5; Gilles Cambonie1, MD,
PhD; for the GFRUP Respiratory Study Group*.
Affiliations: 1Pediatric Intensive Care Unit,
Arnaud de Villeneuve University Hospital, Montpellier, France;2Clinical Research and Epidemiology Unit, CHU
Montpellier, Univ Montpellier, Montpellier, France;3Pediatric Intensive Care Unit, Woman-Mother-Child
University Hospital, Lyon, France; 4 Pediatric
Intensive Care Unit, University Hospital Caen-Normandy, France5Pediatric Intensive Care Unit, Grenoble University
Hospital, La Tronche, France;
*The members of the GFRUP Respiratory Study Group are listed in the
acknowledgments.
Correspondence: Christophe Milesi, MD, Department of Neonatal
Medicine and Pediatric Intensive Care, Arnaud de Villeneuve University
Hospital, 371 Avenue Doyen G Giraud, 34295 Montpellier Cedex 5, France.
Tel +33(0)467 336 609, Fax: +33(0)467 336 228, E-mail:c-milesi@chu-montpellier.fr
Key words: bronchiolitis, high-flow nasal cannula, infant,
failure, risk prediction.
Word counts: text: 1758; Abstract: 320; Tables: 2; Figures: 1
Conflict of interest statement: The authors have no financial
relationships and no potential conflicts of interest relevant to this
article to disclose.